CardiologyNowNews.org CardiologyNowNews.org
Font ResizerAa
  • Home
    • About
      • Message from the Editor-in-Chief
      • Mission Statement
      • Editorial Board
  • News
  • Topics
    • Acute Coronary Syndrome
    • Arrhythmia and Electrophysiology
    • Cardiovascular Imaging
    • Cardiovascular Intervention
    • Cardiovascular Prevention
    • Cerebrovascular Disease
    • Heart Failure
    • Peripheral Vascular Disease
    • Structural Heart Disease
    • Valvular Heart Disease
  • Educational Resources
    • WikiDoc
    • BAIM Grand Rounds
    • Clinical Trial Results
  • ACC
    • ACC 2017
    • ACC 2018
    • ACC 2019
    • ACC 2020
    • ACC 2021
    • ACC 2022
    • ACC 2023
    • ACC 2024
    • ACC 2025
    • ACC 2026
  • AHA
    • AHA 2017
    • AHA 2019
    • AHA 2021
    • AHA 2022
    • AHA 2023
    • AHA 2024
    • AHA 2025
    • AHA 2026
  • ESC
    • ESC 2017
    • ESC 2018
    • ESC 2019
    • ESC 2021
    • ESC 2022
    • ESC 2023
    • ESC 2024
    • ESC 2025
  • SCAI
    • SCAI 2017
    • SCAI 2018
  • Videos
CardiologyNowNews.org CardiologyNowNews.org
Font ResizerAa
Search
  • Home
    • About
  • News
  • Topics
    • Acute Coronary Syndrome
    • Arrhythmia and Electrophysiology
    • Cardiovascular Imaging
    • Cardiovascular Intervention
    • Cardiovascular Prevention
    • Cerebrovascular Disease
    • Heart Failure
    • Peripheral Vascular Disease
    • Structural Heart Disease
    • Valvular Heart Disease
  • Educational Resources
    • WikiDoc
    • BAIM Grand Rounds
    • Clinical Trial Results
  • ACC
    • ACC 2017
    • ACC 2018
    • ACC 2019
    • ACC 2020
    • ACC 2021
    • ACC 2022
    • ACC 2023
    • ACC 2024
    • ACC 2025
    • ACC 2026
  • AHA
    • AHA 2017
    • AHA 2019
    • AHA 2021
    • AHA 2022
    • AHA 2023
    • AHA 2024
    • AHA 2025
    • AHA 2026
  • ESC
    • ESC 2017
    • ESC 2018
    • ESC 2019
    • ESC 2021
    • ESC 2022
    • ESC 2023
    • ESC 2024
    • ESC 2025
  • SCAI
    • SCAI 2017
    • SCAI 2018
  • Videos
Follow US
AHA 2026

SYNCHRONIZE-CVOT: Survodutide Passes Cardiovascular Safety Test

Michael O'Riordan
Share
6 Min Read

CHICAGO, IL—Survodutide, a dual agonist of the glucagon and glucagon-like peptide 1 receptors, cleared one hurdle last week when investigators reported the treatment did not cause cardiovascular harm in high-risk patients with obesity.

The investigational incretin-based therapy met the prespecified noninferiority criterion for cardiovascular safety versus placebo in more than 5,500 patients with obesity and established cardiovascular disease, chronic kidney disease (CKD), or two or more weight-related cardiovascular risk factors.    

“Historically, we have learned that not everything that reduces blood glucose is safe,” said Biykem Bozkurt, MD (Baylor College of Medicine, Houston, TX), at the American Heart Association Scientific Sessions. “Right now, the perception [is that] all incretin-based therapies are similar to each other, but they are not. This being a new drug with glucagon, and glucagon’s known cardiovascular effects, I think it was very important to conduct a safety trial.”

In 2008, the US Food and Drug Administration (FDA) mandated large cardiovascular outcomes trials (CVOTs) for any new diabetes drug, a move prompted by concerns about the thiazolidinedione class of glucose-lowering drugs. In 2020, the FDA relaxed the mandate, shifting to establishing minimum requirements for safety in phase 3 trials.

Complementary Metabolic Effects

The metabolic effects of GLP-1 receptor agonism include glucose control and weight loss, as well as the promotion of satiety, and glucagon receptor agonism exerts complementary metabolic effects, said Bozkurt. Such effects include enhanced lipid metabolism in the liver, fatty acid oxidation, and energy expenditure.    

SYNCHRONIZE-CVOT, which was published simultaneously in The Lancet, was a cardiovascular safety trial of survodutide (3.6 and 6.0 mg) conducted in 34 countries. Adults with a body mass index ≥ 27 kg/m2 and established cardiovascular disease or at least two weight-related cardiovascular risk factors, as well as patients with CKD who had a BMI ≥ 30 kg/m2, were included in the study.

The 5-point MACE endpoint at a median follow-up of 22 months occurred in 3.7% of the 3,671 patients in the pooled survodutide group and 4.1% of the 1,836 placebo-treated patients (HR 0.89; 95% CI 0.67-1.18), a difference that fell within the noninferiority upper bound of 1.65 (P<0.0001 for noninferiority). The 3-point MACE endpoint of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke occurred in 2.4% and 2.8% of the survodutide- and placebo-treated patients (HR 0.84; 95% CI 0.60-1.18; P<0.0001 for noninferiority).

Patients treated with survodutide lost between 12.2% and 13.7% of their body weight and also had significant improvements in their systolic blood pressure, lipid profiles, glycemic control, and high-sensitivity C-reactive protein levels.

Right now, the perception [is that] all incretin-based therapies are similar to each other, but they are not.

Biykem Bozkurt, MD, PhD

In all, 28.6% of the pooled survodutide-treated patients stopped treatment because of adverse effects, primarily gastrointestinal, compared with 11.1% of the placebo group. Bozkurt said most of these events occurred when the dose was uptitrated. The incidence of hypotension and hypoglycemia was slightly elevated with survodutide; the adjusted mean heart rate was 4-5 beats per minute higher with survodutide treatment, said Bozkurt.

Stephen Nicholls, MBBS, PhD (Monash Victorian Heart Institute, Melbourne, Australia), the discussant following the late-breaking presentation, said that while the trial shows there is no harm with survodutide, nothing can be said about cardiovascular benefit, which is a limitation.   

“When we design our clinical trials from a regulatory perspective, it seems it’s a relatively low bar to simply show that there’s no cardiovascular harm,” said Nicholls. “We need to think more and more about how we design clinical trials with what’s important for our patients and the clinicians they are working with.”

While the trial may reassure regulators, Nicholls said he’d like to see a move away from placebo comparators and toward active-comparator studies. Also, an emphasis on patient-centered outcomes would be welcomed, particularly as clinicians are faced with multiple agents available for the treatment of obesity and cardiovascular risk.  

“We need to be able to see how we can use these therapies so that we can triage the right patient to the right drug at the right time of their disease process,” he said.

Source:

Bozkurt B, le Roux CW, Wharton S, et al. Cardiovascular outcomes with survodutide in adults with obesity at increased cardiovascular risk (SYNCHRONIZE-CVOT): a double-blind, randomized, placebo-controlled phase 3 trial. The Lancet. Published online November 9, 2026.

Disclosures:

Bozkurt reports consulting/advisor fees from ABIOMED/Johnson and Johnson, AstraZeneca, Bayer, Bristol Myers Squibb, Boehringer Ingelheim, Cardurion, Cytokinetics, Eli Lilly, Medtronic, Merck, Idorsia, Novo Nordisk, Regeneron, Renovacor, Roche, Salubris, Sanofi-Aventis, scPharmaceuticals, Vasa Therapeutics (DSMC), Vifor, and Respicardia/Zoll; honoraria for lectures or presentations from ABIOMED/Johnson and Johnson, AstraZeneca, Bayer, Boehringer Ingelheim, and Medtronic; travel support from ABIOMED/Johnson and Johnson, Bayer, Boehringer Ingelheim, Medtronic, Merck, and Roche; and advisory board membership for Novo Nordisk, Regeneron, Renovacor, Salubris, and Vasa Therapeutics.

Nicholls reports consulting for Abcentra, AstraZeneca, Amarin, Akcea, Eli Lilly, Anthera, Omthera, Merck, Takeda, Resverlogix, CRISPR, Sanofi-Regeneron, CSL Behring, Esperion, Boehringer Ingelheim, Daiichi Sankyo, and Scribe Therapeutic; he reports research funding from AstraZeneca, CRISPR, NewAmsterdam Pharma, Amgen, Anthera, Cyclarity, Eli Lilly, Esperion, Novartis, Cerenis, The Medicines Company, Resverlogix, InfraReDx, Roche, Sanofi-Regeneron, and LipoScience.

TAGGED:ConferenceFeaturedNews
Share This Article
Copy Link Print
CardiologyNowNews.org CardiologyNowNews.org
Copyright - CardiologyNowNews
  • Contact Us
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?